Trials / Completed
CompletedNCT01455428
Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)
An 8-week Randomized, Double Blind, Multi-center, Placebo-controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin ( 300mg/Day ) Using A Fixed Dosing Schedule In The Treatment Of Subjects With Postherpetic Neuralgia ( Phn )
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 223 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To prove pregabalin is effective in relieving pain compared with placebo in subjects with postherpetic neuralgia (PHN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lyrica (pregabalin) | Capsule, 300 mg/d, BID, 8 weeks treatment |
| DRUG | Placebo | Capsule, 300 mg/d, BID, 8 weeks treatment |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2011-10-20
- Last updated
- 2021-01-28
- Results posted
- 2015-05-22
Locations
22 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01455428. Inclusion in this directory is not an endorsement.